PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Non-small cell lung cancer (NSCLC) is a prevalent malignancy.
• Immunotherapy, particularly targeting the PD-1/PD-L1 pathway, has emerged as a significant treatment modality.
• Tumor cells can exploit PD-L1 expression to evade immune surveillance.

Purpose of the Study:

• To review the role of immunotherapeutic agents in NSCLC treatment.
• To discuss the function of PD-1 and its ligands (PD-L1, PD-L2) in immune evasion.
• To evaluate the prognostic and predictive value of PD-L1 and PD-1 expression in NSCLC.

Main Methods:

• Review of current literature on PD-1/PD-L1 inhibitors in NSCLC.
• Analysis of clinical trial data regarding response rates and survival.
• Examination of studies investigating PD-L1 and PD-1 as biomarkers.

Main Results:

• Immunotherapy has led to FDA approval of PD-1 inhibitors like pembrolizumab and nivolumab for NSCLC.
• These agents show remarkable responses and survival prolongation in 14-20% of chemo-resistant NSCLC patients.
• Elevated PD-L1 expression correlates with higher efficacy of immunotherapeutic agents, suggesting predictive value.

Conclusions:

• Immunotherapy targeting PD-1/PD-L1 represents a breakthrough in NSCLC treatment.
• PD-L1 expression is a promising predictive biomarker for immunotherapy response in NSCLC.
• The prognostic significance of PD-1 and PD-L1 expression in NSCLC requires further investigation.